KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke, Christine I Chen, Norbert Grzasko, George Follows, Zoltán Mátrai, Alessandro Sanna, Lugui Qiu, Ru Feng, Vu Minh Hua, Wojciech Jurczak, Matthias Ritgen, Shuhua Yi, Francesc Bosch, Catherine C Coombs, Katherine Bao, Vishalkumar Patel, Bin Liu, Livia Compte, Ananya Guntur, Denise Y Wang, Marisa Hill, Ching Ching Leow, Paolo Ghia, Paul M Barr

J Clin Oncol 43(22) 2538-2549

PMID40479620
PMCIDPMC12288890
DOI10.1200/JCO-25-00166
发表日期2025-06-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG 4.:森林图/亚组分析图;FIG A1.:森林图/亚组分析图;另有 1 张未列出。
摘要

摘要

PURPOSE: Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted exclusively in patients with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with cBTKi, and compared pirtobrutinib with investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR). METHODS: Patients were randomly assigned 1:1 to receive pirtobrutinib (200 mg once daily) or IC of IdelaR or BR, and were stratified by previous use of venetoclax and del(17p). The primary end point was independent review committee-assessed progression-free survival (PFS). Secondary end points included time to next treatment or death (TTNT), overall survival (OS), and safety. The primary PFS end point was met at the time of the primary analysis (August 29, 2023), and updated results are reported from the final OS analysis (August 29, 2024). RESULTS: A total of 238 patients were randomly assigned to receive pirtobrutinib (n = 119) or IC (n = 119; IdelaR [n = 82], BR [n = 37]). The PFS hazard ratio (HR) was 0.54 ([95% CI, 0.39 to 0.75]; P = .0002), with a median PFS of 14 months (95% CI, 11.2 to 16.6) in the pirtobrutinib group and 8.7 months (95% CI, 8.1 to 10.4) with IC. The unadjusted OS HR was 1.09 ([95% CI, 0.68 to 1.75]; P = .7202), and 18-month OS rate was 73.4% (95% CI, 63.9 to 80.7) in the pirtobrutinib group and 70.8% (95% CI, 60.9 to 78.7) with IC. Median TTNT was 24 months (95% CI, 17.8 to 29.7) with pirtobrutinib versus 10.9 months (95% CI, 8.7 to 12.5) with IC (HR, 0.37 [95% CI, 0.25 to 0.52]). At a median follow-up of 17.2 months, grade ≥3 treatment-emergent adverse events (AEs) were lower with pirtobrutinib (57.7%) than IC (73.4%). Treatment discontinuation due to AE occurred in 20 (17.2%) patients receiving pirtobrutinib and 38 (34.9%) patients receiving IC. CONCLUSION: Pirtobrutinib improved PFS and TTNT, and demonstrated favorable tolerability, versus IdelaR/BR in exclusively cBTKi pretreated patients with CLL/SLL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.CONSORT diagram. Eligible patients receiving the investigator's choice could crossover to receive pirtobrutinib upon confirmation of PD by IRC per protocol. Visit cut: August 29, 2024. a The remaining 17 patients discontinued treatment. b Among patients whose event was investigator-assessed PD and thus had the opportunity to crossover. BR, bendamustine plus rituximab; IdelaR, idelalisib plus rituximab; IRC, independent review committee; PD, disease progression.
非 KM Figure
FIG 2.Kaplan-Meier curve of PFS as assessed by (A) IRC and (B) investigator. *Nominal P value. BR, bendamustine plus rituximab; HR, hazard ratio; IdelaR, idelalisib plus rituximab; IRC, independent review committee; PFS, progression-free survival.
非 KM Figure
FIG 3.Kaplan-Meier curve of (A) event-free survival and (B) overall survival. *Nominal P value. BR, bendamustine plus rituximab; HR, hazard ratio; IdelaR, idelalisib plus rituximab; NE, not estimable.
非 KM Figure
FIG 4.Time to next treatment or death in the (A) ITT population, (B) venetoclax-naïve patients, and (C) venetoclax-treated patients. *Nominal P value. BR, bendamustine plus rituximab; HR, hazard ratio; IdelaR, idelalisib plus rituximab; ITT, intention-to-treat; NE, not estimable.
非 KM Figure
FIG A1.Forest plot of IRC-assessed PFS across patient subgroups treated. a Complex karyotype (yes = ≥3 chromosomal abnormalities; no ≤3 chromosomal abnormalities). b Highly complex karyotype (yes = ≥5 chromosomal abnormalities; no = <5 chromosomal abnormalities). BR, bendamustine plus rituximab; cBTKi, covalent Bruton tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; ECOG, Eastern Cooperative Oncology Group; IdelaR, idelalisib plus rituximab; IGHV, immunoglobulin heavy chain gene; IRC, independent review committee; IWRS, Interactive Web Response System; PD, progressive disease; PFS, progression-free survival; SLL, small lymphocytic lymphoma.
非 KM Figure
FIG A2.Forest plot of TTNT across subgroups. a ≥3 abnormalities in same clonal population. BCL2, B-cell lymphoma-2; BR, bendamustine plus rituximab; cBTKi, covalent Bruton tyrosine kinase inhibitor; CLL, chronic lymphocytic leukemia; ECOG, Eastern Cooperative Oncology Group; IdelaR, idelalisib plus rituximab; IGHV, immunoglobulin heavy chain gene; IWRS, Interactive Web Response System; NE, not estimable; PD, progressive disease; SLL, small lymphocytic lymphoma; TTNT, time to next treatment or death.
非 KM Figure